{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:31:33Z","timestamp":1786991493447,"version":"build-2736575974"},"reference-count":129,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Society of Cytopathology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jasc.2022.08.002","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T10:12:31Z","timestamp":1660903951000},"page":"403-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Molecular testing of cytology specimens: overview of assay selection with focus on lung, salivary gland, and thyroid testing"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7234-5652","authenticated-orcid":false,"given":"Paul A.","family":"VanderLaan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinchita","family":"Roy-Chowdhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Griffith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0874-3207","authenticated-orcid":false,"given":"Vivian L.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7047-4031","authenticated-orcid":false,"given":"Christine N.","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jasc.2022.08.002_bib1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/cyt.12276","article-title":"Diagnostic molecular cytopathology - a further decade of progress","volume":"26","author":"Salto-Tellez","year":"2015","journal-title":"Cytopathology"},{"key":"10.1016\/j.jasc.2022.08.002_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.5858\/apra.2017-0258-ED","article-title":"More than a decade of molecular diagnostic cytopathology leading diagnostic and therapeutic decision-making","volume":"142","author":"Salto-Tellez","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2022.08.002_bib3","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1038\/s41379-018-0138-z","article-title":"The utilization of cytologic and small biopsy samples for ancillary molecular testing","volume":"32","author":"Roh","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/jclinpath-2017-204561","article-title":"How to prepare cytological samples for molecular testing","volume":"70","author":"Bellevicine","year":"2017","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib5","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.5858\/arpa.2016-0117-RA","article-title":"Preanalytic variables in cytology: lessons learned from next-generation sequencing\u2014The MD Anderson Experience","volume":"140","author":"Roy-Chowdhuri","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2022.08.002_bib6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jasc.2020.04.014","article-title":"Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management","volume":"9","author":"Sung","year":"2020","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/cncy.21850","article-title":"Preanalytic specimen triage: smears, cell blocks, cytospin preparations, transport media, and cytobanking","volume":"125","author":"da Cunha Santos","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib8","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/dc.22820","article-title":"The role of cytology specimens in molecular testing of solid tumors: techniques, limitations, and opportunities","volume":"40","author":"Aisner","year":"2012","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-019-02559-z","article-title":"Invited review-next-generation sequencing: a modern tool in cytopathology","volume":"475","author":"Roy-Chowdhuri","year":"2019","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jasc.2022.08.002_bib10","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/cyt.12974","article-title":"Next generation sequencing in cytology","volume":"32","author":"Pisapia","year":"2021","journal-title":"Cytopathology"},{"key":"10.1016\/j.jasc.2022.08.002_bib11","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/cyt.12265","article-title":"Challenges and opportunities of next-generation sequencing: a cytopathologist's perspective","volume":"26","author":"Vigliar","year":"2015","journal-title":"Cytopathology"},{"key":"10.1016\/j.jasc.2022.08.002_bib12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/modpathol.2016.228","article-title":"Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies","volume":"30","author":"Roy-Chowdhuri","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib13","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/cncy.21897","article-title":"Next-generation sequencing of cytologic preparations: an analysis of quality metrics","volume":"125","author":"Hwang","year":"2017","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/cncy.21476","article-title":"Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue","volume":"123","author":"Gailey","year":"2015","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib15","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.5858\/arpa.2016-0108-RA","article-title":"Optimizing workflows and processing of cytologic samples for comprehensive analysis by next-generation sequencing: Memorial Sloan Kettering Cancer Center experience","volume":"140","author":"Tian","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2022.08.002_bib16","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jasc.2022.08.002_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.14694\/EdBook_AM.2014.34.177","article-title":"50 years of progress in the systemic therapy of non-small cell lung cancer","author":"Wakelee","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jasc.2022.08.002_bib19","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.14694\/EdBook_AM.2014.34.e353","article-title":"Management and future directions in non-small cell lung cancer with known activating mutations","author":"Gerber","year":"2014","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"suppl 1","key":"10.1016\/j.jasc.2022.08.002_bib20","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.21037\/tcr.2017.02.28","article-title":"Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease","volume":"6","author":"Rangachari","year":"2017","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.jasc.2022.08.002_bib21","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cllc.2017.04.004","article-title":"Genomic profiling of advanced non-small cell lung cancer in community settings: gaps and opportunities","volume":"18","author":"Gutierrez","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jasc.2022.08.002_bib22","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jasc.2022.08.002_bib23","series-title":"Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Non-Small Cell Lung Cancer Version 3","author":"National Comprehensive Care Network","year":"2022"},{"key":"10.1016\/j.jasc.2022.08.002_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cncy.22334","article-title":"The rapidly evolving landscape of biomarker testing in non-small cell lung cancer","volume":"129","author":"VanderLaan","year":"2021","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","article-title":"The evolving landscape of biomarker testing for non-small cell lung cancer in Europe","volume":"154","author":"Kerr","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jasc.2022.08.002_bib26","doi-asserted-by":"crossref","first-page":"933","DOI":"10.5858\/arpa.2020-0119-CP","volume":"144","author":"Roy-Chowdhuri","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2022.08.002_bib27","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jasc.2020.04.001","article-title":"Collection and handling of thoracic small biopsy and cytology specimens for ancillary studies guideline from the College of American Pathologists (CAP): implications for the cytology community","volume":"9","author":"VanderLaan","year":"2020","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib28","doi-asserted-by":"crossref","first-page":"828","DOI":"10.5858\/arpa.2012-0720-OA","volume":"137","author":"Lindeman","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2022.08.002_bib29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2022.08.002_bib31","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jasc.2022.08.002_bib32","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jasc.2022.08.002_bib33","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1002\/cncy.22313","article-title":"Current and future trends in non-small cell lung cancer biomarker testing: the American experience","volume":"128","author":"VanderLaan","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jasc.2019.01.006","article-title":"Diagnostic utility of fluorescence in situ hybridization testing on cytology cell blocks for the definitive classification of salivary gland neoplasms","volume":"8","author":"Darras","year":"2019","journal-title":"J Am Soc Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cyt.12427","article-title":"Use of fluorescent in-situ hybridisation in salivary gland cytology: a powerful diagnostic tool","volume":"28","author":"Evrard","year":"2017","journal-title":"Cytopathology"},{"key":"10.1016\/j.jasc.2022.08.002_bib36","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/cncy.21693","article-title":"Usefulness of translocation-associated immunohistochemical stains in the fine-needle aspiration diagnosis of salivary gland neoplasms","volume":"124","author":"Foo","year":"2016","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib37","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/PAS.0b013e3181de3021","article-title":"A reappraisal of the MECT1\/MAML2 translocation in salivary mucoepidermoid carcinomas","volume":"34","author":"Seethala","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/PAS.0000000000001252","article-title":"Mucoepidermoid carcinoma: a comparison of histologic grading systems and relationship to MAML2 rearrangement and prognosis","volume":"43","author":"Cipriani","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib39","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.3390\/ijms23084322","article-title":"Diagnostic value of MAML2 rearrangements in mucoepidermoid carcinoma","volume":"23","author":"Thierauf","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jasc.2022.08.002_bib40","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00428-021-03146-x","article-title":"Mucoepidermoid carcinoma of the salivary glands revisited with special reference to histologic grading and CRTC1\/3-MAML2 genotyping","volume":"479","author":"Fehr","year":"2021","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jasc.2022.08.002_bib41","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/path.2327","article-title":"POU5F1, encoding a key regulator of stem cell pluripotency, is fused to EWSR1 in hidradenoma of the skin and mucoepidermoid carcinoma of the salivary glands","volume":"215","author":"M\u00f6ller","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib42","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e3181d9efcc","article-title":"Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity","volume":"34","author":"Sk\u00e1lov\u00e1","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib43","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/PAS.0000000000001535","article-title":"Expanding the molecular spectrum of secretory carcinoma of salivary glands with a novel VIM-RET fusion","volume":"44","author":"Sk\u00e1lov\u00e1","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib44","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/PAS.0000000000000972","article-title":"Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 cases","volume":"42","author":"Sk\u00e1lov\u00e1","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib45","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/PAS.0000000000001065","article-title":"Salivary secretory carcinoma with a novel ETV6-MET fusion: expanding the molecular spectrum of a recently described entity","volume":"42","author":"Rooper","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.humpath.2018.08.011","article-title":"Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family","volume":"83","author":"Guilmette","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib47","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/PAS.0000000000001471","article-title":"Salivary secretory carcinoma harboring a novel ALK fusion: expanding the molecular characterization of carcinomas beyond the ETV6 gene","volume":"44","author":"Sasaki","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib48","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/apm.12950","article-title":"Cytopathological features of secretory carcinoma of salivary glands and ancillary techniques in its diagnostics: impact of new Milan system for reporting salivary gland cytopathology","volume":"127","author":"Miesbauerov\u00e1","year":"2019","journal-title":"APMIS"},{"key":"10.1016\/j.jasc.2022.08.002_bib49","first-page":"264","article-title":"Using pan-TRK and RET immunohistochemistry for the detection of fusion types of salivary gland secretory carcinoma","volume":"30","author":"Su","year":"2022","journal-title":"Appl Immunohistochem Mol Morphol AIMM"},{"key":"10.1016\/j.jasc.2022.08.002_bib50","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1097\/PAS.0000000000001718","article-title":"Pan-TRK immunohistochemistry is highly correlated with NTRK3 gene rearrangements in salivary gland tumors","volume":"45","author":"Csanyi-Bastien","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib51","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/his.13981","article-title":"Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion","volume":"76","author":"Xu","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.jasc.2022.08.002_bib52","doi-asserted-by":"crossref","first-page":"E329","DOI":"10.1002\/dc.24750","article-title":"Utility of an immunocytochemical analysis for pan-Trk in the cytodiagnosis of secretory carcinoma of the salivary gland","volume":"49","author":"Ito","year":"2021","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib53","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12920-022-01155-6","article-title":"Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report","volume":"15","author":"Suzuki","year":"2022","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.jasc.2022.08.002_bib54","doi-asserted-by":"crossref","first-page":"478","DOI":"10.6004\/jnccn.2021.7022","article-title":"Clinical activity of selitrectinib in a patient with mammary analogue secretory carcinoma of the parotid gland with secondary resistance to entrectinib","volume":"19","author":"Florou","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jasc.2022.08.002_bib55","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41467-018-08069-x","article-title":"Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands","volume":"10","author":"Haller","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jasc.2022.08.002_bib56","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1097\/PAS.0000000000001279","article-title":"Nuclear NR4A3 immunostaining is a specific and sensitive novel marker for acinic cell carcinoma of the salivary glands","volume":"43","author":"Haller","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2020.05.001","article-title":"NOR-1 distinguishes acinic cell carcinoma from its mimics on fine-needle aspiration biopsy specimens","volume":"102","author":"Nguyen","year":"2020","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib58","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/gcc.22979","article-title":"Targeted RNA sequencing in the routine clinical detection of fusion genes in salivary gland tumors","volume":"60","author":"Bubola","year":"2021","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.jasc.2022.08.002_bib59","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/dc.24714","article-title":"BOC-PLAG1, a new fusion gene of pleomorphic adenoma: Identified in a fine-needle aspirate by RNA next-generation sequencing","volume":"49","author":"Pei","year":"2021","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib60","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/his.13759","article-title":"Clinicopathological effect of PLAG1 fusion genes in pleomorphic adenoma and carcinoma ex pleomorphic adenoma with special emphasis on histological features","volume":"74","author":"Asahina","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.jasc.2022.08.002_bib61","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/PAS.0000000000001783","article-title":"HMGA2-WIF1 rearrangements characterize a distinctive subset of salivary pleomorphic adenomas with prominent trabecular (canalicular adenoma-like) morphology","volume":"46","author":"Agaimy","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib62","first-page":"63","article-title":"HMGA2 immunoexpression is frequent in salivary gland pleomorphic adenoma: immunohistochemical and molecular analyses of PLAG1 and HMGA2 in 25 cases","volume":"15","author":"Owosho","year":"2022","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib63","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/his.13246","article-title":"HMGA2 is a specific immunohistochemical marker for pleomorphic adenoma and carcinoma ex-pleomorphic adenoma","volume":"71","author":"Mito","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.jasc.2022.08.002_bib64","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000447622","article-title":"PLAG1: an immunohistochemical marker with limited utility in separating pleomorphic adenoma from other basaloid salivary gland tumors","volume":"60","author":"Avadhani","year":"2016","journal-title":"Acta Cytol"},{"key":"10.1016\/j.jasc.2022.08.002_bib65","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/PAS.0000000000000933","article-title":"Epithelial-myoepithelial carcinoma: frequent morphologic and molecular evidence of preexisting pleomorphic adenoma, common HRAS mutations in PLAG1-intact and HMGA2-intact cases, and occasional TP53, FBXW7, and SMARCB1 alterations in high-grade cases","volume":"42","author":"El Hallani","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib66","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/cncr.30179","article-title":"Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations","volume":"122","author":"Chiosea","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jasc.2022.08.002_bib67","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.humpath.2014.08.017","article-title":"Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts","volume":"46","author":"Katabi","year":"2015","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib68","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/his.12152","article-title":"An analysis of PLAG1 and HMGA2 rearrangements in salivary duct carcinoma and examination of the role of precursor lesions","volume":"63","author":"Bahrami","year":"2013","journal-title":"Histopathology"},{"key":"10.1016\/j.jasc.2022.08.002_bib69","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s12105-012-0353-8","article-title":"PLAG1 alteration in carcinoma ex pleomorphic adenoma: immunohistochemical and fluorescence in situ hybridization studies of 22 cases","volume":"6","author":"Bahrami","year":"2012","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib70","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.oooo.2021.03.020","article-title":"Detection of novel fusion genes by next-generation sequencing-based targeted RNA sequencing analysis in adenoid cystic carcinoma of head and neck","volume":"132","author":"Shibata","year":"2021","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.jasc.2022.08.002_bib71","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/PAS.0000000000001616","article-title":"MYB RNA in situ hybridization facilitates sensitive and specific diagnosis of adenoid cystic carcinoma regardless of translocation status","volume":"45","author":"Rooper","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib72","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s12105-020-01202-7","article-title":"The utility of MYB immunohistochemistry (IHC) in fine needle aspiration (FNA) diagnosis of adenoid cystic carcinoma (AdCC)","volume":"15","author":"Sun","year":"2021","journal-title":"Head Neck Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib73","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/jop.12617","article-title":"Immunohistochemical expression of MYB in salivary gland basal cell adenocarcinoma and basal cell adenoma","volume":"46","author":"Rooney","year":"2017","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.jasc.2022.08.002_bib74","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/dc.23551","article-title":"MYB expression: potential role in separating adenoid cystic carcinoma (ACC) from pleomorphic adenoma (PA)","volume":"44","author":"Moon","year":"2016","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib75","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41379-018-0008-8","article-title":"MYB and MYBL1 in adenoid cystic carcinoma: diversity in the mode of genomic rearrangement and transcripts","volume":"31","author":"Togashi","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib76","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/path.5006","article-title":"MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene","volume":"244","author":"Kim","year":"2018","journal-title":"J Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib77","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1634\/theoncologist.2018-0515","article-title":"Clinically integrated molecular diagnostics in adenoid cystic carcinoma","volume":"24","author":"Thierauf","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.jasc.2022.08.002_bib78","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41379-021-00999-0","article-title":"ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing","volume":"35","author":"Ferguson","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib79","doi-asserted-by":"crossref","first-page":"102069","DOI":"10.1016\/j.ctrv.2020.102069","article-title":"Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: a systematic review","volume":"89","author":"Uijen","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jasc.2022.08.002_bib80","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1002\/cam4.2602","article-title":"Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling","volume":"8","author":"Gargano","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jasc.2022.08.002_bib81","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/PAS.0b013e3182880d5a","article-title":"PIK3CA mutations and PTEN loss in salivary duct carcinomas","volume":"37","author":"Griffith","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib82","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1097\/PAS.0000000000001698","article-title":"ALK rearrangements characterize 2 distinct types of salivary gland carcinomas: clinicopathologic and molecular analysis of 4 cases and literature review","volume":"45","author":"Agaimy","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib83","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.humpath.2019.03.004","article-title":"The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement","volume":"88","author":"Dogan","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib84","series-title":"The Bethesda System for Reporting Thyroid Cytopathology, criteria and explanatory notes","author":"Ali","year":"2018"},{"key":"10.1016\/j.jasc.2022.08.002_bib85","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrendo.2011.142","article-title":"Molecular genetics and diagnosis of thyroid cancer","volume":"7","author":"Nikiforov","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jasc.2022.08.002_bib86","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jasc.2022.08.002_bib87","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncy.21199","article-title":"Cytomorphological and molecular genetic findings in pediatric thyroid fine-needle aspiration","volume":"120","author":"Monaco","year":"2012","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib88","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1089\/thy.2014.0312","article-title":"Can malignant thyroid nodules be distinguished from benign thyroid nodules in children and adolescents by clinical characteristics? A review of 89 pediatric patients with thyroid nodules","volume":"25","author":"Buryk","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.jasc.2022.08.002_bib89","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1089\/thy.2021.0317","article-title":"Unique molecular signatures are associated with aggressive histology in pediatric differentiated thyroid cancer","volume":"32","author":"Mollen","year":"2022","journal-title":"Thyroid"},{"key":"10.1016\/j.jasc.2022.08.002_bib90","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/jamaoncol.2022.1655","article-title":"Evaluation of the molecular landscape of pediatric thyroid nodules and use of a multigene genomic classifier in children","volume":"8","author":"Gallant","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jasc.2022.08.002_bib91","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/cncr.30708","article-title":"Molecular testing for thyroid nodules: review and current state","volume":"124","author":"Roth","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jasc.2022.08.002_bib92","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrendo.2014.115","article-title":"Pax-8-PPAR-gamma fusion protein in thyroid carcinoma","volume":"10","author":"Raman","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jasc.2022.08.002_bib93","doi-asserted-by":"crossref","first-page":"6586","DOI":"10.1158\/1078-0432.CCR-04-0053","article-title":"Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications","volume":"10","author":"Chevillard","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jasc.2022.08.002_bib94","doi-asserted-by":"crossref","first-page":"15044","DOI":"10.1073\/pnas.251547398","article-title":"Gene expression in papillary thyroid carcinoma reveals highly consistent profiles","volume":"98","author":"Huang","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jasc.2022.08.002_bib95","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1158\/0008-5472.CAN-03-3811","article-title":"Using gene expression profiling to differentiate benign versus malignant thyroid tumors","volume":"64","author":"Mazzanti","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.jasc.2022.08.002_bib96","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1210\/jc.2007-2696","article-title":"MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility","volume":"93","author":"Nikiforova","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jasc.2022.08.002_bib97","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1210\/jc.2008-0273","article-title":"Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase\/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers","volume":"93","author":"Liu","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jasc.2022.08.002_bib98","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ccell.2018.07.002","article-title":"Integrated genomic analysis of Hurthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes","volume":"34","author":"Ganly","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jasc.2022.08.002_bib99","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ccell.2018.06.013","article-title":"Widespread chromosomal losses and mitochondrial dna alterations as genetic drivers in Hurthle cell carcinoma","volume":"34","author":"Gopal","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jasc.2022.08.002_bib100","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.1002\/cam4.2467","article-title":"Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer","volume":"8","author":"Panebianco","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.jasc.2022.08.002_bib101","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/cncr.33421","article-title":"Risk assessment for distant metastasis in differentiated thyroid cancer using molecular profiling: a matched case-control study","volume":"127","author":"Yip","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.jasc.2022.08.002_bib102","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1186\/s12885-015-1955-9","article-title":"The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy","volume":"15","author":"Kasaian","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jasc.2022.08.002_bib103","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1385\/EP:15:4:319","article-title":"Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas","volume":"15","author":"Nikiforov","year":"2004","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib104","doi-asserted-by":"crossref","first-page":"8031","DOI":"10.1038\/s41598-020-64635-8","article-title":"Molecular profile of locally aggressive well differentiated thyroid cancers","volume":"10","author":"Mady","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jasc.2022.08.002_bib105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/cncy.22331","article-title":"Thyroid cytology smear slides: an untapped resource for ThyroSeq testing","volume":"129","author":"Nikiforova","year":"2021","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib106","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/dc.23902","article-title":"Utilization of direct smears of thyroid fine-needle aspirates for ancillary molecular testing: a comparison of two proprietary testing platforms","volume":"46","author":"Partyka","year":"2018","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib107","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5858\/arpa.2017-0136-OA","article-title":"Next-generation sequencing identifies gene mutations that are predictive of malignancy in residual needle rinses collected from fine-needle aspirations of thyroid nodules","volume":"142","author":"Fuller","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jasc.2022.08.002_bib108","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41379-018-0006-x","article-title":"Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling","volume":"31","author":"Roy-Chowdhuri","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib109","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/cncy.22098","article-title":"Centrifuged supernatants from FNA provide a liquid biopsy option for clinical next-generation sequencing of thyroid nodules","volume":"127","author":"Ye","year":"2019","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib110","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/cncy.22454","article-title":"How limited molecular testing can also offer diagnostic and prognostic evaluation of thyroid nodules processed with liquid-based cytology: role of TERT promoter and BRAF V600E mutation analysis","volume":"129","author":"Dell'Aquila","year":"2021","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib111","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.7150\/jca.46086","article-title":"Risk stratification study of indeterminate thyroid nodules with a next-generation sequencing assay with residual ThinPrep(R) material","volume":"11","author":"Zhao","year":"2020","journal-title":"J Cancer"},{"key":"10.1016\/j.jasc.2022.08.002_bib112","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/cncy.22270","article-title":"Preanalytic variables in quality and quantity of nucleic acids extracted from FNA specimens of thyroid gland nodules collected in CytoLyt: Cellularity and storage time","volume":"128","author":"Heymann","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib113","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.humpath.2011.04.010","article-title":"BRAF(V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma","volume":"43","author":"Chang","year":"2012","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib114","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1210\/clinem\/dgab304","article-title":"Afirma genomic sequencing classifier and Xpression Atlas molecular findings in consecutive Bethesda III-VI thyroid nodules","volume":"106","author":"Hu","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jasc.2022.08.002_bib115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/cncy.22088","article-title":"Benign call rate and molecular test result distribution of ThyroSeq v3","volume":"127","author":"Ohori","year":"2019","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib116","first-page":"301280","article-title":"The role of the ThyroSeq v3 molecular test in the surgical management of thyroid nodules in the Canadian public health care setting","author":"Chen","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.jasc.2022.08.002_bib117","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/cncy.22362","article-title":"ThyroSeq v3 for Bethesda III and IV: an institutional experience","volume":"129","author":"Desai","year":"2021","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib118","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/cncy.22188","article-title":"Performance of the Afirma genomic sequencing classifier versus gene expression classifier: an institutional experience","volume":"127","author":"Wei","year":"2019","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib119","doi-asserted-by":"crossref","first-page":"dgz099","DOI":"10.1210\/clinem\/dgz099","article-title":"Real-world comparison of Afirma GEC and GSC for the assessment of cytologically indeterminate thyroid nodules","volume":"105","author":"San Martin","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jasc.2022.08.002_bib120","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/thy.2018.0726","article-title":"Independent comparison of the Afirma genomic sequencing classifier and gene expression classifier for cytologically indeterminate thyroid nodules","volume":"29","author":"Angell","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.jasc.2022.08.002_bib121","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1530\/ERC-20-0435","article-title":"Molecular alterations in Hurthle cell nodules and preoperative cancer risk","volume":"28","author":"Doerfler","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jasc.2022.08.002_bib122","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4158\/EP-2018-0395","article-title":"Statistical comparison of Afirma Gsc and Afirma Gec outcomes in a community endocrine surgical practice: early findings","volume":"25","author":"Harrell","year":"2019","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jasc.2022.08.002_bib123","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamaoncol.2018.4616","article-title":"Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: a prospective blinded multicenter study","volume":"5","author":"Steward","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jasc.2022.08.002_bib124","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1089\/thy.2020.0021","article-title":"Letter to the editor: Use of molecular diagnostic tests in thyroid nodules with Hurthle cell-dominant cytology","volume":"30","author":"Endo","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.jasc.2022.08.002_bib125","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cncy.22569","article-title":"Copy number variations identified in thyroid FNA specimens are associated with Hurthle cell cytomorphology","volume":"130","author":"Abi-Raad","year":"2022","journal-title":"Cancer Cytopathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib126","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ecl.2017.01.014","article-title":"Molecular genetics of thyroid cancer in children and adolescents","volume":"46","author":"Bauer","year":"2017","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.jasc.2022.08.002_bib127","doi-asserted-by":"crossref","first-page":"dgaa389","DOI":"10.1210\/clinem\/dgaa389","article-title":"Genetic alterations in pediatric thyroid cancer using a comprehensive childhood cancer gene panel","volume":"105","author":"Alzahrani","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jasc.2022.08.002_bib128","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/JCO.21.01861","article-title":"Fusion oncogenes are associated with increased metastatic capacity and persistent disease in pediatric thyroid cancers","volume":"40","author":"Franco","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jasc.2022.08.002_bib129","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/s41379-020-0458-7","article-title":"Poorly differentiated thyroid carcinoma of childhood and adolescence: a distinct entity characterized by DICER1 mutations","volume":"33","author":"Chernock","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jasc.2022.08.002_bib130","doi-asserted-by":"crossref","DOI":"10.1159\/000526116","article-title":"Indeterminate thyroid fine-needle aspirations in pediatrics: exploring the clinicopathologic features and utility of molecular profiling","author":"Baran","year":"2022","journal-title":"Horm Res Paediatr"},{"key":"10.1016\/j.jasc.2022.08.002_bib131","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Journal of the American Society of Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213294522002423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213294522002423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T06:48:11Z","timestamp":1761979691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213294522002423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":129,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2213294522002423"],"URL":"https:\/\/doi.org\/10.1016\/j.jasc.2022.08.002","relation":{},"ISSN":["2213-2945"],"issn-type":[{"value":"2213-2945","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular testing of cytology specimens: overview of assay selection with focus on lung, salivary gland, and thyroid testing","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Society of Cytopathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jasc.2022.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Society of Cytopathology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}